Quick Answer
Stoke Therapeutics, Inc. reported Stockholders Equity of $352.46 million for fiscal year 2025.
Stoke Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $352.46M | +53.9% |
| 2024 | $229.02M | +43.5% |
| 2023 | $159.56M | -13.7% |
| 2022 | $184.85M | -15.1% |
| 2021 | $217.78M | -23.9% |
| 2020 | $286.08M | +27.5% |
| 2019 | $224.43M | +113.6% |
| 2018 | $105.07M | +8232.2% |
| 2017 | -$1.29M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $308.11M | +32.7% | -8.0% |
| June 30, 2025 | $334.94M | +38.0% | -4.3% |
| March 31, 2025 | $350.07M | +149.4% | +52.9% |
| December 31, 2024 | $229.02M | +43.5% | -1.3% |
| September 30, 2024 | $232.11M | +34.2% | -4.4% |
| June 30, 2024 | $242.71M | +27.6% | +72.9% |
| March 31, 2024 | $140.34M | -34.4% | -12.0% |
| December 31, 2023 | $159.56M | -13.7% | -7.8% |
- Stoke Therapeutics, Inc. showed an increase of +53.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, Stoke Therapeutics, Inc.’s stockholders equity has grown by 27380.0% (from -$1.29 million to $352.46 million).
- The most recent figure is from Stoke Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: